Celgene Gets Another Myeloma CAR-T Accepted Onto EMA’s PRIME
Executive Summary
Bristol-Myers Squibb’s newly acquired company Celgene is one of two drug sponsors that this month made it onto the European Medicines Agency’s priority medicines scheme. The other is Achillion Pharmaceuticals, which is developing a treatment for paroxysmal nocturnal hemoglobinuria.
You may also be interested in...
With Celgene Acquisition Closed, Bristol Faces Major Milestones
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
Myeloma BCMA Therapy In Spotlight: EMA Considers Fast Tracking GSK Filing
The European Medicines Agency is this week deciding whether GlaxoSmithKline’s planned EU marketing application for its BCMA-targeting therapy merits an accelerated assessment.
Alexion Buys A Complementary Business With Achillion
The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.